Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | KDR | P35968 | 2/20 | 0.71 |
| ▸ | UBE2M | P61081 | 9/20 | 0.66 |
| ▸ | DCUN1D1 | Q96GG9 | 9/20 | 0.66 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18658207 | 0.90 | HIF1A (0.65) | EGFRKDRUBE2MDCUN1D1MEN1 | |
| SCHEMBL18387540 | 0.84 | EGFR (1.00) | EGFRKDRBRAFMAPK14TNNI3K | |
| SCHEMBL18387544 | 0.84 | EGFR (1.00) | EGFRKDRBRAFMAPK14TNNI3K | |
| SCHEMBL18657601 | 0.82 | SMN1; SMN2 (0.67) | EGFRKDRMEN1MAPTRAB9A | |
| SCHEMBL18657525 | 0.80 | HPGD (0.68) | UBE2MDCUN1D1MEN1MAPTHTT | |
| SCHEMBL18640262 | 0.79 | DCUN1D1 (1.00) | UBE2MDCUN1D1MEN1MAPTHTT | |
| SCHEMBL31499162 | 0.79 | DCUN1D1 (1.00) | UBE2MDCUN1D1MEN1MAPTHTT | |
| SCHEMBL18640396 | 0.79 | DCUN1D1 (1.00) | UBE2MDCUN1D1MEN1KMT2AALDH1A1 | |
| SCHEMBL31499152 | 0.79 | DCUN1D1 (1.00) | UBE2MDCUN1D1MEN1KMT2AALDH1A1 | |
| SCHEMBL20557951 | 0.79 | TNIK (0.60) | MEN1MAPTKMT2AKDM4ETNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2017049295-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | EGFR 4878/4885KDR 4835/4885UBE2M 8/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | EGFR 4878/4885KDR 4835/4885UBE2M 8/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | EGFR 4878/4885KDR 4835/4885UBE2M 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.